Abbisko Therapeutics Co., Ltd., a leading biotech company, has reached a significant milestone in the development of its novel CSF-1R inhibitor, pimicotinib. The company announced the successful completion of patient enrollment for the pivotal Phase III clinical trial, MANEUVER STUDY, which aims to evaluate the efficacy and safety of pimicotinib in patients with tenosynovial giant cell tumor (TGCT).
The global, multi-center, randomized, double-blind, placebo-controlled Phase III trial has met its target enrollment goal as of April 9, 2024. The study’s primary objective is to assess the efficacy of pimicotinib in reducing tumor volume and improving patient outcomes in TGCT, a rare and debilitating condition affecting the synovial joints.
Abbisko Therapeutics’ dedication to advancing innovative therapies for rare diseases is exemplified by the swift progression of pimicotinib through clinical development. The completion of patient enrollment in the MANEUVER STUDY brings the company one step closer to potentially offering a new treatment option for patients with TGCT.
